当前位置:首页 - 行情中心 - 易明医药(002826) - 财务分析 - 利润表

易明医药

(002826)

  

流通市值:14.77亿  总市值:16.00亿
流通股本:1.76亿   总股本:1.91亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入538,300,734.55376,435,471.58171,430,742.25856,734,307.99
营业收入538,300,734.55376,435,471.58171,430,742.25856,734,307.99
二、营业总成本524,441,373.68363,512,513.02163,151,787.75822,310,337.1
营业成本275,484,285.18206,728,744.6795,466,688.58480,560,417.18
税金及附加9,489,994.167,236,902.173,147,117.0412,046,790.91
销售费用188,372,110.24119,473,983.8754,762,059.47270,673,384.96
管理费用40,294,917.4824,405,489.589,582,396.4147,245,337.07
研发费用11,672,853.416,238,257.2498,451.9113,353,738.55
财务费用-872,786.79-570,864.47-304,925.66-1,569,331.57
其中:利息费用1,105,300.02886,966.68411,111.08810,555.75
其中:利息收入2,128,470.131,595,425.45730,755.392,449,984.42
加:公允价值变动收益-151,385.03--
加:投资收益862,231.64654,779.39-1,481,272.54
资产减值损失(新)----141,618.87
信用减值损失(新)2,261,975.043,506,956.371,755,052.14-3,338,753.1
其他收益13,150,938.78973,674.88664,159.8323,304,491.38
营业利润平衡项目0000
四、营业利润30,134,506.3318,209,754.2310,698,166.4755,729,362.84
加:营业外收入343,685.73120,866.6358,199.531,798,017.75
减:营业外支出626,064.42266,763.14111,016.02824,779.97
利润总额平衡项目0000
五、利润总额29,852,127.6418,063,857.7210,645,349.9856,702,600.62
减:所得税费用5,452,331.313,412,066.182,166,477.3310,586,663.67
六、净利润24,399,796.3314,651,791.548,478,872.6546,115,936.95
持续经营净利润24,399,796.3314,651,791.548,478,872.6546,115,936.95
归属于母公司股东的净利润23,887,952.9214,080,751.768,363,504.1244,135,409.23
少数股东损益511,843.41571,039.78115,368.531,980,527.72
(一)基本每股收益0.130.070.040.23
(二)稀释每股收益0.130.070.040.23
八、其他综合收益1,040,284.751,424,774.51-87,171.94-3,729.63
归属于母公司股东的其他综合收益1,040,284.751,424,774.51-87,171.94-3,729.63
九、综合收益总额25,440,081.0816,076,566.058,391,700.7146,112,207.32
归属于母公司股东的综合收益总额24,928,237.6715,505,526.278,276,332.1844,131,679.6
归属于少数股东的综合收益总额511,843.41571,039.78115,368.531,980,527.72
公告日期2023-10-302023-08-232023-04-272023-04-27
审计意见(境内)标准无保留意见
TOP↑